Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England

To assess the degree to which reimbursement prices in Australia and England differ for a range of generic drugs, and to analyse the supply- and demand-side factors that may contribute to these differences.

The global biopharma industry and the rise of Indian drug multinationals: implication for Australian generics policy

This article provides a synopsis of the new dynamics of the global biopharma industry. The emergence of global generics companies with capabilities approximating those of 'big pharma' has accelerated the blurring of boundaries between the innovator and generics sectors. Biotechnology-based products form a large and growing segment of prescription drug markets and regulatory pathways for biogenerics are imminent. Indian biopharma multinationals with large-scale efficient manufacturing plants and growing R&D capabilities are now major suppliers of Active Pharmaceutical Ingredients (APIs) and generic drugs across both developed and developing countries. In response to generic competition, innovator companies employ a range of life cycle management techniques, including the launch of 'authorised generics'. The generics segment in Australia will see high growth rates in coming years but the prospect for local manufacturing is bleak. The availability of cheap generics in international markets has put pressure on Pharmaceutical Benefits Scheme (PBS) pricing arrangements, and a new policy direction was announced in November 2006. Lower generics prices will have a negative impact on some incumbent suppliers but industrial renewal policies for the medicines industry in Australia are better focused on higher value R&D activities and niche manufacturing of sophisticated products.

Alcohol Price Considerations on alcohol and Illicit Drug Use in University Students

Background
This study investigates alcohol price and proposed substance use amongst Australian tertiary students.

Methods
Participants were recruited in 2009 via facebook, and were asked to complete a 34-item internetbased survey. 512 people took part, 485 fit the inclusion criteria.

Results
The sample consisted predominately of young (mean age 20.3 years), female (66%) university students. Higher alcohol prices resulted in increased consideration of illicit substances as an alternative indicating a substitution effect, although the majority (60%) of respondents would never consider using ecstasy.

Conclusion
Results indicate substantial room to increase the price of alcohol to achieve alcohol consumption reduction without likely substitution behavior.